Sacubitril/valsartan quadrupled protective ANP peptide levels over 6 months and halved diuretic requirements in heart failure patients.
102 → 409 pg/mLANP peptide levels quadrupled over 6 months in patients on sacubitril/valsartan, while ACE inhibitor patients saw no change
What the researchers found
Sacubitril/valsartan treatment significantly increased atrial natriuretic peptide (ANP) levels in patients with compensated heart failure — from a median of 102 pg/mL at baseline to 283 pg/mL at 3 months and 409 pg/mL at 6 months. Simultaneously, the daily furosemide (loop diuretic) dose was cut in half, from 40 mg to 20 mg. No such changes occurred in the ACE inhibitor comparison group.
Patients with preserved ejection fraction (HFpEF) and persistent atrial fibrillation showed the largest ANP increases, with odds ratios of 7.558 and 4.649 respectively for high ANP elevation.
Why it matters
Natriuretic peptides are the heart's own protective hormones — they lower blood pressure, reduce fluid retention, and protect against cardiac stress. Sacubitril works by blocking neprilysin, the enzyme that breaks down these peptides. This study shows that blocking neprilysin measurably raises ANP levels and allows patients to reduce their diuretic doses, suggesting a shift from artificial fluid management to the body's own peptide-driven system.
The numbers in context
ANP: 102→283→409 pg/mL; furosemide: 40→20 mg; OR 7.558 for HFpEF; OR 4.649 for persistent AF
How the study worked
Prospective observational study comparing 42 outpatients with compensated heart failure receiving sacubitril/valsartan to 39 patients on ACE inhibitors, with natriuretic peptide levels and diuretic doses measured at baseline, 3 months, and 6 months.
Who was studied
81 Asian outpatients with compensated heart failure (42 on sacubitril/valsartan, 39 on ACE inhibitors)
What this study cannot tell us
Non-randomized observational design means the two groups may differ in unmeasured ways. The sample size of 81 patients is modest. The study focused on an Asian cohort, which may limit generalizability to other populations.
How to read the evidence
This is a prospective observational study with 81 patients. While it provides useful time-course data, the non-randomized design and modest sample size place it below randomized controlled trials in evidence strength.
When this study was published
Published in 2023, this study provides recent data on how neprilysin inhibition affects natriuretic peptide dynamics in an Asian heart failure cohort.
The bigger picture
Sacubitril/valsartan represents a paradigm shift in heart failure treatment — rather than replacing the body's systems with drugs, it amplifies the heart's own natriuretic peptide defense. This study adds time-course data showing how peptide levels respond and identifies which patients (HFpEF with atrial fibrillation) may benefit most from this peptide-preserving approach.
Questions still open
- Does the sustained ANP increase translate into better long-term heart failure outcomes in this population?
- Why do patients with HFpEF and atrial fibrillation show the largest ANP response to neprilysin inhibition?
- Could ANP levels serve as a biomarker to guide sacubitril/valsartan dosing?
Common questions
What are natriuretic peptides and why do they matter in heart failure?
Why did patients need less diuretic medication on sacubitril/valsartan?
Read the original research
Effect of sacubitril/valsartan on natriuretic peptide in patients with compensated heart failure.
Heart and vessels, 38(6), 773-784
Citation
Shirakabe, Akihiro; Matsushita, Masato; Sawatani, Tomofumi; Noma, Satsuki; Takayasu, Tsutomu; Kanai, Hideki; Asano, Miwako; Nomura, Akiko; Asai, Kuniya. (2023). Effect of sacubitril/valsartan on natriuretic peptide in patients with compensated heart failure.. Heart and vessels, 38(6), 773-784. https://doi.org/10.1007/s00380-022-02230-9